Antibody Pipeline
While making full use of our unique technological achievements in fully human antibody production, POTELLIGENTR® and COMPLEGENT® technologies, Kyowa Hakko Kirin continues to make new advances in research and development on therapeutic antibodies.
Antibody Pipeline (July 2010)
| Therapeutic Areas | Code Name | Country / Stage | Indication | Remarks |
|---|---|---|---|---|
| Cancer | KW-0761 | Japan Phase 2 |
Cancer (Hematologic tumor) |
|
| U.S. Phase 1/2a |
||||
| Cancer | KRN330 | U.S. Phase 1/2a |
Cancer |
|
| Cancer | BIW-8962 | U.S. Phase 1/2a |
Cancer |
|
| Immunology / Allergy | ASKP1240 | Phase 1 | Organ Transplant Rejection |
|
| Immunology / Allergy | KHK4563 | Japan Phase 1 |
Asthma |
|
| Other | KRN23 | U.S. Phase 1 |
Hypophosphatemic disease such as X-linked Hypophosphatemia (XLH) |
|
Outlicensed Antibodies
KW-0761 [Anti-CCR4 humanized monoclonal antibody, utilizing the POTELLIGENT® technology platform]
CCR4 is a chemokine receptor that binds specifically to its ligands TARC and MDC, and participates in the control of T cell migration. CCR4 is expressed mainly on Th2-type helper T cells and regulatory T cells in normal conditions. CCR4+ T cells are implicated in the pathology of asthma and other inflammatory diseases and T-cell malignancies.
KW-0761 is a humanized monoclonal antibody targeting CCR4 utilizing the POTELLIGENT® technology platform for the development of therapies for CCR4+ T cell-related diseases.
- News Release; March 6, 2008
BIW-8405 [Anti-IL5R humanized monoclonal antibody, utilizing the POTELLIGENT® technology platform]
BIW-8405 targeting asthma is outlicensed to MedImmune, Inc. (USA) on December 19th, 2006.
BIW-8405 is a fully humanized afucosylated IgG1 anti-IL-5R alpha chain monoclonal antibody. It neutralizes IL-5 activity and depletes tissue eosinophils which are believed to play a key role in the pathogenesis of asthma in pre-clinical models with an acceptable toxicology profile.
KW-2871 [Anti-GD3 chimeric monoclonal antibody]
KW-2871 is a chimeric monoclonal antibody specifically binding to the ganglioside antigen, GD3, expressed on the surface of malignant melanoma cells and is expected to treat mallignant melanoma by antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
- News Release; March 6, 2007
Anti LIGHT fully human monoclonal antibody
LIGHT molecule was discovered by La Jolla Institute for Allergy and Immunology (LIAI), is a key mediator of inflammation, and enhances several immune cells. The antibody against LIGHT was created by both Kyowa Hakko Kirin California, a wholly-owned subsidiary of Kyowa Hakko Kirin, and LIAI. It could become an immune-regulatory agent with a novel mode of action, and expected to be the first in class in Ulcerative Colitis and in Crohn's disease. The development could be pursued in further indications such as Rheumatoid Arthritis.
